温通法联合化疗对耐药后的肺腺癌患者临床疗效观察  

Clinical Effects observation of warming-to-unblocking therapy combined with chemotherapy on ressistant Lung adenocarcinoma Patients

作　　者：边猛[1] 杨亚琴[2] 

机构地区：[1]河南中医学院,硕士研究生河南郑州450000 [2]河南省中医院,河南郑州450002

出　　处：《中医临床研究》2014年第33期67-69,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的：研究温通法联合化疗对表皮生长因子受体酪氨酸激酶抑制剂类药物耐药后的脾’肾阳虚型肺腺癌患者的近期疗效，以及对生活质量、毒副反应等的影响。方法：42例入组患者随机分为治疗组（温通类中药联合化疗）20例与对照组（单纯化疗）22例，分别观察客观疗效、生活质量、毒副反应。结果：治疗组的有效率为35％，KPS评分提高率为60％，Ⅲ-Ⅳ度骨髓抑制（白细胞降低）发生率为15％。对照组的有效率为28％，KPS评分提高为36％，Ⅲ-Ⅳ度骨髓抑制发生率为45％。结论：温通法联合化疗对EGFR-TKIS耐药后的脾肾阳虚型肺腺癌患者可提高生活质量与客观疗效。Objective： To investigate short-term effects of warming-to-unblocking therapy combined with chemotherapy on lung adenocarcinoma patients of spleen and kidney yang-deficiency who were resistant to drugs of epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKLs）, as well as effects on life quality and toxicity etc. Methods： 42 cases were randomly divided into treatment group （warming-to-unblocking herbal medicine combined with chemotherapy） of 20 and control group （only chemotherapy） of 22. And clinical effects, life quality and toxicity were separately observed. Results： The effective rate of the treatment group was 35% and KPS scores increased 60%, with 15% occurrence of Ill-IV myelosuppression; while the effective rate of the control group was 28% and KPS scores increased 36%, with 45% occurrence of Ill-IV myelosuppression. Conclusion： The warming-to-unblocking therapy combined with chemotherapy on patients of lung adenocarcinoma of spleen and kidney yang-deficiency who were ressistant to EGFR-TKLs.

关 键 词：温通法 肺腺癌 临床疗效 

分 类 号：R273[医药卫生—中西医结合]